WO2024064721A3 - Methods of treating disorders associated with eya overexpression and mutations - Google Patents
Methods of treating disorders associated with eya overexpression and mutations Download PDFInfo
- Publication number
- WO2024064721A3 WO2024064721A3 PCT/US2023/074639 US2023074639W WO2024064721A3 WO 2024064721 A3 WO2024064721 A3 WO 2024064721A3 US 2023074639 W US2023074639 W US 2023074639W WO 2024064721 A3 WO2024064721 A3 WO 2024064721A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- eya
- methods
- overexpression
- disorders associated
- Prior art date
Links
- 230000002018 overexpression Effects 0.000 title abstract 2
- 230000035772 mutation Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010008342 Cervix carcinoma Diseases 0.000 abstract 1
- 206010011878 Deafness Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010881 cervical cancer Diseases 0.000 abstract 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 abstract 1
- 208000016097 disease of metabolism Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 230000010370 hearing loss Effects 0.000 abstract 1
- 231100000888 hearing loss Toxicity 0.000 abstract 1
- 208000016354 hearing loss disease Diseases 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- XELRMPRLCPFTBH-UHFFFAOYSA-N quinazoline-2,4-diamine Chemical class C1=CC=CC2=NC(N)=NC(N)=C21 XELRMPRLCPFTBH-UHFFFAOYSA-N 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present disclosure is concerned with methods of treating disorders associated with overexpression of an eyes absent (EYA) protein such as, for example, vascular disease, a fibrosis-related disorder, hearing loss, and a metabolic disease using quinazoline-2,4- diamines. Also disclosed are methods of treating cancer that comprises a tumor that overexpresses at least one eyes absent (EYA) protein (e.g, breast cancer, cervical cancer, ovarian cancer, liver cancer, pancreatic cancer, pediatric cancers). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263408398P | 2022-09-20 | 2022-09-20 | |
| US63/408,398 | 2022-09-20 | ||
| US202363502876P | 2023-05-17 | 2023-05-17 | |
| US63/502,876 | 2023-05-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2024064721A2 WO2024064721A2 (en) | 2024-03-28 |
| WO2024064721A3 true WO2024064721A3 (en) | 2024-05-02 |
Family
ID=90455193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2023/074639 WO2024064721A2 (en) | 2022-09-20 | 2023-09-20 | Methods of treating disorders associated with eya overexpression and mutations |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2024064721A2 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090048278A1 (en) * | 2005-12-07 | 2009-02-19 | Ulrik Svane Sorensen | Novel Quinazoline-2,4-Diamine Derivatives and Their Use as Modulators of Small-Conductance Calcium-Activated Potassium Channels |
| US20140155420A1 (en) * | 2011-01-10 | 2014-06-05 | The Regents Of The University Of Colorado, A Body Corporate | Inhibitors of eya2 |
| US20210130312A1 (en) * | 2018-04-03 | 2021-05-06 | Children's Hospital Medical Center | Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension |
| WO2023133221A2 (en) * | 2022-01-06 | 2023-07-13 | Board Of Regents, The University Of Texas System | Smarca2/4 inhibition as a strategy to treat tumors that harbor aberrant baf assemblies |
-
2023
- 2023-09-20 WO PCT/US2023/074639 patent/WO2024064721A2/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090048278A1 (en) * | 2005-12-07 | 2009-02-19 | Ulrik Svane Sorensen | Novel Quinazoline-2,4-Diamine Derivatives and Their Use as Modulators of Small-Conductance Calcium-Activated Potassium Channels |
| US20140155420A1 (en) * | 2011-01-10 | 2014-06-05 | The Regents Of The University Of Colorado, A Body Corporate | Inhibitors of eya2 |
| US20210130312A1 (en) * | 2018-04-03 | 2021-05-06 | Children's Hospital Medical Center | Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension |
| WO2023133221A2 (en) * | 2022-01-06 | 2023-07-13 | Board Of Regents, The University Of Texas System | Smarca2/4 inhibition as a strategy to treat tumors that harbor aberrant baf assemblies |
Non-Patent Citations (1)
| Title |
|---|
| MOHAMED ET AL.: "Structure-Activity Relationship Studies of Isomeric 2,4-Diaminoquinazolines on ß-Amyloid Aggregation Kinetics", ACS MEDICINAL CHEMISTRY LETTERS, vol. 7, 3 January 2016 (2016-01-03), pages 502 - 507, XP055624212, DOI: 10.1021/acsmedchemlett.6b00039 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024064721A2 (en) | 2024-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020009514A (en) | Anti-claudin 18.2 antibodies. | |
| AU2005253776A8 (en) | Screening methods using c-Abl, Fyn and Syk in combination with tau protein | |
| CR20210501A (en) | Protein tyrosine phosphatase inhibitors | |
| MX2010005966A (en) | Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7). | |
| Iijima et al. | Core fucose is critical for CD14-dependent Toll-like receptor 4 signaling | |
| BR0005394A (en) | Progressively added lenses with variable power profiles | |
| WO2003020906A3 (en) | Multivalent protein conjugate with multiple ligand-binding domains of receptors | |
| EA201201067A1 (en) | METHOD FOR PRODUCING binding molecules specific to proteins associated with the disorder or an antibody or binding fragment thereof or at least one immunoglobulin chains LINKING aforementioned PROTEIN (VARIANTS) binding molecules, antibodies, CIRCUIT immunoglobulins or their binding fragments (VARIANTS) , POLYNUCLEOTIDE, VECTOR AND CELL-HOST, THEIR INCLUDING COMPOSITION | |
| MXPA05008521A (en) | Antibodies to c-met for the treatment of cancers. | |
| WO2003072125A8 (en) | Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides | |
| MX2007001638A (en) | Binding domain fusion proteins. | |
| MX2014003677A (en) | Fusion proteins for treating metabolic disorders. | |
| EP2644204A3 (en) | Combinations of an Anti-HER2 antibody-drug conjugate and pertuzumab | |
| EA201390739A1 (en) | METHOD OF TREATING FGF21-ASSOCIATED DISORDERS | |
| EA200700212A1 (en) | MULTI-VALUE VLA-4 ANTAGONISTS CONTAINING POLYMER FRAGMENTS | |
| WO2008083326A3 (en) | Targeting of ews-fli1 as anti-tumor therapy | |
| WO2005023202A3 (en) | Tumor suppressor lkb1 kinase directly activates amp-activated kinase | |
| WO2021003469A3 (en) | Recombinant human sialidases, sialidase fusion proteins, and methods of using the same | |
| WO2024064721A3 (en) | Methods of treating disorders associated with eya overexpression and mutations | |
| BR112023020773A2 (en) | COMPOUNDS, PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING CANCER, FOR REGULATING THE ACTIVITY OF A MUTANT PROTEIN, FOR INHIBITING THE PROLIFERATION OF A CELL POPULATION, FOR PREPARING A MUTANT PROTEIN AND FOR INHIBITING TUMOR METASTASIS, USE OF A COMPOUND AND PROCESS FOR SYNTHESISTING A COMPOUND | |
| MX2020011487A (en) | Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof. | |
| Wang et al. | Cell fusion in cancer hallmarks: Current research status and future indications | |
| WO2015089495A3 (en) | Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders | |
| WO2005120504A3 (en) | Cancer treatment method | |
| ATE288960T1 (en) | HUMANIZED MONOCLONAL ANTIBODIES WITH HIGH AFFINITY AGAINST DAY-72 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23869124 Country of ref document: EP Kind code of ref document: A2 |